ClinicalTrials.gg
CompletedNCT00291187Updated Oct 15, 2014Results posted

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

A Phase 3 interventional study of 20 mg VEC-162 and 50 mg VEC-162 in Insomnia, sponsored by Vanda Pharmaceuticals. Completed at 19 sites in United States. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-15.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
411
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 146 open to participants now, 183 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.

Enrollment
75th of 855
411 · median 60
Started
2006
with 41 others
Phase 3
68 of 903
4 open now
Registered
41st of 903
by date

Among the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 75th largest by enrollment of the 855 interventional ones that give a count, is one of 42 that started in 2006, is one of 68 in phase 3, and was the 41st registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

146 of the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:

141 more — sign in →

All 146 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 21 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.

03

Conditions studied

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects with no medical, psychiatric or current sleep disorders.
  • Subject must sign a written consent form.

Exclusion criteria

Exclusion Criteria:

  • Recent history of night shift work or jet lag.
  • Prior experience sleeping in a sleep lab environment.
  • History of sleep disorders.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
411 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Take orally 30 minutes prior to bedtime.

    Drug: Placebo

  • Experimental
    20 mg VEC-162

    20 mg taken orally 30 minutes prior to bedtime.

    Drug: 20 mg VEC-162

  • Experimental
    50 mg VEC-162

    50 mg taken orally 30 minutes prior to bedtime.

    Drug: 50 mg VEC-162

  • Experimental
    100 mg VEC-162

    100 mg taken orally 30 minutes prior to bedtime.

    Drug: 100 mg VEC-162

Interventions

06

What researchers measure

Primary outcomes

  1. Average Improvement of Latency to Persistent Sleep (LPS)

    The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.

    Time frame: Night 1

Secondary outcomes

  1. Average Improvement of Wake After Sleep Onset (WASO)

    The average improvement of wake after sleep onset (time spent awake between onset of sleep and lights on, determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.

    Time frame: Night 1

07

Results

Posted Oct 15, 2014

Participant flow

Recruitment took place at 20 US sites. The first subject was screened on February 9th 2006, the first subject enrolled on March 10th, 2006, and the last subject completed on August 21st 2006.

Participant flow — Overall Study
MilestonePlaceboVEC-162 20 mgVEC-162 50 mgVEC-162 100 mg
Started103100103106
Completed103100102106
Not completed0010
Withdrew: Protocol violation- no drug administered0010

Outcome measures

PrimaryAverage Improvement of Latency to Persistent Sleep (LPS)

The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.

Time frame:
Night 1
Reported as:
Mean · minutes
Average Improvement of Latency to Persistent Sleep (LPS)
minutesPlaceboVEC-162 20 mgVEC-162 50 mgVEC-162 100 mg
Average Improvement of Latency to Persistent Sleep (LPS)45.8 ± 4.2824.3 ± 4.3519.6 ± 4.3123.1 ± 4.21
Statistical analysis
  • Placebo vs VEC-162 20 mg · ANCOVA · p = <0.001 · Mean difference (final values): -21.5 · 95% CI -33.1 to -9.9
  • Placebo vs VEC-162 50 mg · ANCOVA · p = <0.001 · Mean difference (final values): -26.3 · 95% CI -37.8 to -14.7
  • Placebo vs VEC-162 100 mg · ANCOVA · p = <0.001 · Mean difference (final values): -22.8 · 95% CI -34.2 to -11.3
SecondaryAverage Improvement of Wake After Sleep Onset (WASO)

The average improvement of wake after sleep onset (time spent awake between onset of sleep and lights on, determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.

Time frame:
Night 1
Reported as:
Mean · minutes
Average Improvement of Wake After Sleep Onset (WASO)
minutesPlaceboVEC-162 20 mgVEC-162 50 mgVEC-162 100 mg
Average Improvement of Wake After Sleep Onset (WASO)139.3 ± 7.33115.1 ± 7.46105.6 ± 7.39121.9 ± 7.22
Statistical analysis
  • Placebo vs VEC-162 20 mg · ANCOVA · p = 0.017 · Mean difference (final values): -24.2 · 95% CI -44.1 to -4.3
  • Placebo vs VEC-162 50 mg · ANCOVA · p = 0.001 · Mean difference (final values): -33.7 · 95% CI -53.6 to -13.9
  • Placebo vs VEC-162 100 mg · ANCOVA · p = 0.081 · Mean difference (final values): -17.4 · 95% CI -37.0 to 2.1
Post-hocAverage Improvement in Total Sleep Time (TST)

The average improvement in Total sleep time (determined by PSG and defined as the number of non-wake minutes between lights off and lights on) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.

Time frame:
Night 1
Reported as:
Mean · Minutes
Average Improvement in Total Sleep Time (TST)
MinutesPlaceboVEC-162 20 mgVEC-162 50 mgVEC-162 100 mg
Average Improvement in Total Sleep Time (TST)317.6 ± 7.65351.4 ± 7.78365.5 ± 7.71347.2 ± 7.53
Statistical analysis
  • Placebo vs VEC-162 20 mg · ANCOVA · p = 0.002 · Mean difference (final values): 33.7 · 95% CI 13.0 to 54.5
  • Placebo vs VEC-162 50 mg · ANCOVA · p = <0.001 · Mean difference (final values): 47.9 · 95% CI 27.2 to 68.6
  • Placebo vs VEC-162 100 mg · ANCOVA · p = 0.005 · Mean difference (final values): 29.6 · 95% CI 9.1 to 50.0
Post-hocAverage Improvement in Latency to Non-awake (LNA)

The average improvement in latency to non-awake (length of time elapsed between lights off and first epoch of sleep determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.

Time frame:
Night 1
Reported as:
Mean · Minutes
Average Improvement in Latency to Non-awake (LNA)
MinutesPlaceboVEC-162 20 mgVEC-162 50 mgVEC-162 100 mg
Average Improvement in Latency to Non-awake (LNA)22.3 ± 2.8811.2 ± 2.938.0 ± 2.9010.0 ± 2.84
Statistical analysis
  • Placebo vs VEC-162 20 mg · ANCOVA · p = 0.006 · Mean difference (final values): -11.1 · 95% CI -18.9 to -3.3
  • Placebo vs VEC-162 50 mg · ANCOVA · p = <0.001 · Mean difference (final values): -14.3 · 95% CI -22.1 to -6.5
  • Placebo vs VEC-162 100 mg · ANCOVA · p = 0.002 · Mean difference (final values): -12.3 · 95% CI -20.0 to -4.6

Adverse events

Collected over Day 1 through Day 2.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/103 (0%)5/103 (4.9%)
VEC-162 20 mg—0/100 (0%)7/100 (7%)
VEC-162 50 mg—0/102 (0%)5/102 (4.9%)
VEC-162 100 mg—0/106 (0%)6/106 (5.7%)
Most frequent other events
Most frequent other events
EventPlaceboVEC-162 20 mgVEC-162 50 mgVEC-162 100 mg
NauseaGastrointestinal disorders3/1033/1003/1023/106
HeadacheNervous system disorders3/1030/1001/1021/106
Dry MouthGastrointestinal disorders0/1032/1001/1020/106
Dry ThroatRespiratory, thoracic and mediastinal disorders0/1032/1000/1021/106
Abnormal DreamsPsychiatric disorders0/1031/1002/1021/106
DyspepsiaGastrointestinal disorders0/1030/1001/1022/106

Baseline characteristics

Modified Intent-to-Treat. A total of 411 subjects received treatment.

Age, Continuous
Age, Continuous(years)PlaceboVEC-162 20 mgVEC-162 50 mgVEC-162 100 mgTotal
Mean30.9 ± 7.2830.8 ± 8.4131.0 ± 8.5131.2 ± 8.1931.0 ± 8.08
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVEC-162 20 mgVEC-162 50 mgVEC-162 100 mgTotal
Female68625873261
Male35384433150
08

Study locations

19 sites
  • Vanda Investigational Site
    Birmingham, Alabama, United States
  • Vanda Investigational Site
    Phoenix, Arizona, United States
  • Vanda Investigational Site
    San Diego, California, United States
  • Vanda Investigational Site
    San Francisco, California, United States
  • Vanda Investigational Site
    Santa Monica, California, United States
  • Vanda Investigational Site
    Miami, Florida, United States
  • Vanda Investigational Site
    Naples, Florida, United States
  • Vanda Investigational Site
    Pembroke Pines, Florida, United States
  • Vanda Investigational Site
    St. Petersburg, Florida, United States
  • Vanda Investigational Site
    Atlanta, Georgia, United States
  • Vanda Investigational Site
    Overland Park, Kansas, United States
  • Vanda Investigational Site
    Chevy Chase, Maryland, United States
  • Vanda Investigational Site
    New York, New York, United States
  • Vanda Investigational Site
    Rochester, New York, United States
  • Vanda Investigational Site
    Raleigh, North Carolina, United States
  • Vanda Investigational Site
    Cincinnati, Ohio, United States
  • Vanda Investigational Site
    Columbia, South Carolina, United States
  • Vanda Investigational Site
    Austin, Texas, United States
  • Vanda Investigational Site
    Plano, Texas, United States
09

References and documents

Publications

  • Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009 Feb 7;373(9662):482-91. doi: 10.1016/S0140-6736(08)61812-7. Epub 2008 Dec 4. Erratum In: Lancet. 2009 Apr 11;373(9671):1252. PubMed 19054552 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 8 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2006
First posted
Feb 13, 2006
Start
Feb 2006
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Results first posted
Oct 15, 2014
Last update
Oct 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00291187
Responsible party
Sponsor
First posted
Feb 13, 2006
Start date
Feb 2006
Primary completion
Aug 2006
Completion
Aug 2006
Results posted
Oct 15, 2014
Last update
Oct 15, 2014

Study contacts

Vanda Pharmaceuticals
study director · Vanda Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion